目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Treatment Type
1.2.2. Regional scope
1.2.3. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Treatment Type Outlook
2.2.2. Regional outlook
2.3. Competitive Insights

Chapter 3. Basal Cell Carcinoma Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of target diseases
3.2.1.2. Technological advancements
3.2.1.3. Rising geriatric population
3.2.2. Market restraint analysis
3.2.2.1. Adverse effects associated with treatment.
3.2.2.2. High cost of treatment
3.3. Basal Cell Carcinoma Treatment Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape

Chapter 4. Basal Cell Carcinoma Treatment Market: Treatment Type Estimates & Trend Analysis
4.1. Global Basal Cell Carcinoma Treatment Market: Treatment Type Dashboard
4.2. Global Basal Cell Carcinoma Treatment Market: Treatment Type Movement Analysis
4.3. Global Basal Cell Carcinoma Treatment Market By Treatment Type, Revenue
4.4. Surgery
4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Mohs Surgery
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Surgical Excision
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Electrodesiccation and Curettage (ED&C)
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Radiotherapy (RT)
4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Intralesional Injections
4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Topical Chemotherapy
4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7.2. 5-fluorouracil (5-FU)
4.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7.3. Tirbanibulin (Klisyri)
4.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7.4. Imiquimod (Zyclara)
4.7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Oral Medications
4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.8.2. Vismodegib (Erivedge)
4.8.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.8.3. Sonidegib (Odomzo)
4.8.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Intravenous Medications
4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.10. Chemical Peeling Treatment
4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million).

Chapter 5. Basal Cell Carcinoma Treatment Market: Regional Estimates & Trend Analysis By Treatment Type
5.1. Regional Dashboard
5.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
5.3. North America
5.3.1. U.S.
5.3.1.1. Key country dynamics
5.3.1.2. Regulatory framework/ reimbursement structure
5.3.1.3. Competitive scenario
5.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
5.3.2. Canada
5.3.2.1. Key country dynamics
5.3.2.2. Regulatory framework/ reimbursement structure
5.3.2.3. Competitive scenario
5.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
5.3.3. Mexico
5.3.3.1. Key country dynamics
5.3.3.2. Regulatory framework/ reimbursement structure
5.3.3.3. Competitive scenario
5.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
5.4. Europe
5.4.1. UK
5.4.1.1. Key country dynamics
5.4.1.2. Regulatory framework/ reimbursement structure
5.4.1.3. Competitive scenario
5.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Germany
5.4.2.1. Key country dynamics
5.4.2.2. Regulatory framework/ reimbursement structure
5.4.2.3. Competitive scenario
5.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. France
5.4.3.1. Key country dynamics
5.4.3.2. Regulatory framework/ reimbursement structure
5.4.3.3. Competitive scenario
5.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. Italy
5.4.4.1. Key country dynamics
5.4.4.2. Regulatory framework/ reimbursement structure
5.4.4.3. Competitive scenario
5.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
5.4.5. Spain
5.4.5.1. Key country dynamics
5.4.5.2. Regulatory framework/ reimbursement structure
5.4.5.3. Competitive scenario
5.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
5.4.6. Denmark
5.4.6.1. Key country dynamics
5.4.6.2. Regulatory framework/ reimbursement structure
5.4.6.3. Competitive scenario
5.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
5.4.7. Sweden
5.4.7.1. Key country dynamics
5.4.7.2. Regulatory framework/ reimbursement structure
5.4.7.3. Competitive scenario
5.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
5.4.8. Norway
5.4.8.1. Key country dynamics
5.4.8.2. Regulatory framework/ reimbursement structure
5.4.8.3. Competitive scenario
5.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Asia Pacific
5.5.1. Japan
5.5.1.1. Key country dynamics
5.5.1.2. Regulatory framework/ reimbursement structure
5.5.1.3. Competitive scenario
5.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
5.5.2. China
5.5.2.1. Key country dynamics
5.5.2.2. Regulatory framework/ reimbursement structure
5.5.2.3. Competitive scenario
5.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
5.5.3. India
5.5.3.1. Key country dynamics
5.5.3.2. Regulatory framework/ reimbursement structure
5.5.3.3. Competitive scenario
5.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
5.5.4. Australia
5.5.4.1. Key country dynamics
5.5.4.2. Regulatory framework/ reimbursement structure
5.5.4.3. Competitive scenario
5.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
5.5.5. South Korea
5.5.5.1. Key country dynamics
5.5.5.2. Regulatory framework/ reimbursement structure
5.5.5.3. Competitive scenario
5.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
5.5.6. Thailand
5.5.6.1. Key country dynamics
5.5.6.2. Regulatory framework/ reimbursement structure
5.5.6.3. Competitive scenario
5.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Latin America
5.6.1. Brazil
5.6.1.1. Key country dynamics
5.6.1.2. Regulatory framework/ reimbursement structure
5.6.1.3. Competitive scenario
5.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
5.6.2. Argentina
5.6.2.1. Key country dynamics
5.6.2.2. Regulatory framework/ reimbursement structure
5.6.2.3. Competitive scenario
5.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
5.7. MEA
5.7.1. South Africa
5.7.1.1. Key country dynamics
5.7.1.2. Regulatory framework/ reimbursement structure
5.7.1.3. Competitive scenario
5.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
5.7.2. Saudi Arabia
5.7.2.1. Key country dynamics
5.7.2.2. Regulatory framework/ reimbursement structure
5.7.2.3. Competitive scenario
5.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
5.7.3. UAE
5.7.3.1. Key country dynamics
5.7.3.2. Regulatory framework/ reimbursement structure
5.7.3.3. Competitive scenario
5.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
5.7.4. Kuwait
5.7.4.1. Key country dynamics
5.7.4.2. Regulatory framework/ reimbursement structure
5.7.4.3. Competitive scenario
5.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape
6.1. Company/Competition Categorization
6.2. Participant Overview
6.3. Financial Overview
6.4. Treatment Type Benchmarking
6.5. Company Market Share Analysis, 2023
6.6. Strategy Mapping
6.7. Company Profiles
6.7.1. Bausch Health Companies Inc.
6.7.1.1. Company overview
6.7.1.2. Financial performance
6.7.1.3. Product benchmarking
6.7.1.4. Strategic initiatives
6.7.2. Almirall, S.A.
6.7.2.1. Company overview
6.7.2.2. Financial performance
6.7.2.3. Product benchmarking
6.7.2.4. Strategic initiatives
6.7.3. Genentech, Inc. (Subsidiary of F. Hoffmann-La Roche AG)
6.7.3.1. Company overview
6.7.3.2. Financial performance
6.7.3.3. Product benchmarking
6.7.3.4. Strategic initiatives
6.7.4. Novartis AG.
6.7.4.1. Company overview
6.7.4.2. Financial performance
6.7.4.3. Product benchmarking
6.7.4.4. Strategic initiatives
6.7.5. Regeneron Pharmaceuticals Inc.
6.7.5.1. Company overview
6.7.5.2. Financial performance
6.7.5.3. Product benchmarking
6.7.5.4. Strategic initiatives
6.7.6. Dr Reddy’s Laboratories.
6.7.6.1. Company overview
6.7.6.2. Financial performance
6.7.6.3. Product benchmarking
6.7.6.4. Strategic initiatives
6.7.7. Taro Pharmaceuticals Ltd.
6.7.7.1. Company overview
6.7.7.2. Financial performance
6.7.7.3. Product benchmarking
6.7.7.4. Strategic initiatives
6.7.8. Accord Healthcare Limited (Subsidiary of Intas Pharmaceuticals)
6.7.8.1. Company overview
6.7.8.2. Financial performance
6.7.8.3. Product benchmarking
6.7.8.4. Strategic initiatives

List of Tables
Table 1 List of abbreviation
Table 2 North America basal cell carcinoma market, by region, 2018 - 2030 (USD Million)
Table 3 North America basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 4 U.S. basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 5 Canada basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 6 Mexico basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 7 Europe basal cell carcinoma market, by region, 2018 - 2030 (USD Million)
Table 8 Europe basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 9 Germany basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 10 UK basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 11 France basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 12 Italy basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 13 Spain basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 14 Denmark basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 15 Sweden basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 16 Norway basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 17 Asia Pacific basal cell carcinoma market, by region, 2018 - 2030 (USD Million)
Table 18 Asia Pacific basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 19 China basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 20 Japan basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 21 India basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 22 South Korea basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 23 Australia basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 24 Thailand basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 25 Latin America basal cell carcinoma market, by region, 2018 - 2030 (USD Million)
Table 26 Latin America basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 27 Brazil basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 28 Argentina basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 29 MEA basal cell carcinoma market, by region, 2018 - 2030 (USD Million)
Table 30 MEA basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 31 South Africa basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 32 Saudi Arabia basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 33 UAE basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
Table 34 Kuwait basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Basal cell carcinoma treatments market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 QFD modelling for market share assessment.
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Treatment type segment snapshot
Fig. 10 Competitive landscape snapshot
Fig. 11 Parent market (USD Billion)
Fig. 12 Market dynamics
Fig. 13 Porter’s five forces analysis
Fig. 14 PESTLE analysis
Fig. 15 Basal cell carcinoma treatment market: Treatment type outlook key takeaways
Fig. 16 Basal cell carcinoma treatment market: Treatment type movement analysis
Fig. 17 Surgery market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 Mohs surgery market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 Tumor removal procedures (including skin cancer)
Fig. 20 Surgical excision market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Electrodesiccation and Curettage (ED&C) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Radiotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Intralesional injections market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Topical chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 5-fluorouracil (5-FU) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Tirbanibulin (Klisyri) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Imiquimod (Zyclara) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Oral medications market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Vismodegib (Erivedge) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Sonidegib (Odomzo) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Intravenous medications market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Chemical peeling treatment minimally invasive procedures, 2018 - 2030 (USD Million)
Fig. 33 Chemical peeling treatment market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Basal cell carcinoma treatment market revenue, by region, 2023 & 2030 (USD Million)
Fig. 35 Regional marketplace: Key takeaways
Fig. 36 Regional marketplace: Key takeaways
Fig. 37 North America basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Key country dynamics
Fig. 39 U.S. basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Key country dynamics
Fig. 41 Canada basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Key country dynamics
Fig. 43 Mexico basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Regulatory framework
Fig. 45 Europe basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Key country dynamics
Fig. 47 UK basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Key country dynamics
Fig. 49 Germany basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Key country dynamics
Fig. 51 France basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Key country dynamics
Fig. 53 Spain basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Key country dynamics
Fig. 55 Italy basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 Key country dynamics
Fig. 57 Denmark basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 58 Key country dynamics
Fig. 59 Sweden basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 60 Key country dynamics
Fig. 61 Norway basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 62 Rest of Europe basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 63 Asia Pacific basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 64 Key country dynamics
Fig. 65 Japan basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 Japan pharmaceutical registration
Fig. 67 Key country dynamics
Fig. 68 China basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 Regulatory details: China
Fig. 70 Key country dynamics
Fig. 71 India basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 72 Registration details: India
Fig. 73 Key country dynamics
Fig. 74 Australia basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 Drug pricing: Australia
Fig. 76 Contribution of PBS by disease
Fig. 77 Key country dynamics
Fig. 78 Thailand basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Key country dynamics
Fig. 80 South Korea basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 81 Reimbursement scenario: South Korea
Fig. 82 Rest of Asia Pacific basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 Latin America basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 84 Key country dynamics
Fig. 85 Brazil basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 86 Key country dynamics
Fig. 87 Argentina basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 88 Argentina pharmaceuticals registration details
Fig. 89 Argentina pharmaceuticals reimbursement details
Fig. 90 Rest of Latin America basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 91 MEA basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 92 Key country dynamics
Fig. 93 South Africa basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 94 Regulatory framework: South Africa
Fig. 95 Regulatory framework: South Africa drug registration fees
Fig. 96 Key country dynamics
Fig. 97 Saudi Arabia basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 98 Key country dynamics
Fig. 99 UAE basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 100 Key country dynamics
Fig. 101 Kuwait basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 102 Regulatory framework: Kuwait
Fig. 103 Rest of MEA basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 104 Market participant categorization
Fig. 105 Heat map analysis
Fig. 106 Strategic framework